Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.35 |
| ▸ | EP300 | Q09472 | 4/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870535 | 0.90 | RBP4 (0.39) | RBP4ESR2ADORA1NR1H2PARP1 | |
| SCHEMBL22029633 | 0.86 | RBP4 (0.37) | RBP4ESR2ADORA1NR1H2PARP1 | |
| SCHEMBL14520683 | 0.85 | ESR2 (0.41) | RBP4ESR2ADORA1NR1H2PARP1 | |
| SCHEMBL4792110 | 0.85 | ADORA1 (0.46) | RBP4ESR2ADORA1NR1H2MAPK1 | |
| SCHEMBL25430237 | 0.84 | ADORA1 (0.43) | RBP4ESR2ADORA1NR1H2PARP1 | |
| SCHEMBL17878107 | 0.83 | MAPK1 (0.42) | RBP4ESR2ADORA1NR1H2PARP1 | |
| SCHEMBL22615700 | 0.83 | NAMPT (0.35) | RBP4ESR2ADORA1NR1H2PARP1 | |
| SCHEMBL22029695 | 0.83 | CREBBP (0.42) | RBP4MAPK1CREBBPEP300BRD4 | |
| SCHEMBL22029670 | 0.82 | RBP4 (0.35) | RBP4ESR2ADORA1NR1H2PARP1 | |
| SCHEMBL29386147 | 0.82 | RBP4 (0.42) | RBP4ESR2ADORA1NR1H2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | US | disclosed |
| EP-3976617-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3478683-B1 | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210188849-A1 | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10975077-B2 | Diazepinone derivatives and their use in the treatment of hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| WO-2020243135-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243135-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| US-9890161-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9527845-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527845-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527845-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160185777-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185777-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185777-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | HCCS, SLC10A1, PYGL | RBP4 2939/4885ESR2 1489/4885ADORA1 1063/4885 |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | RBP4 170/4885ESR2 1041/4885ADORA1 2542/4885 |
| US-20160185777-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | RBP4 170/4885ESR2 1041/4885ADORA1 2542/4885 |
| US-20210188849-A1 | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | HAVCR2, NR1H4, NR1H2 | RBP4 2459/4885ESR2 519/4885ADORA1 552/4885 |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | RBP4 3250/4885ESR2 382/4885ADORA1 4456/4885 |
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | RBP4 2316/4885ESR2 1374/4885ADORA1 949/4885 |
| US-10975077-B2 | Diazepinone derivatives and their use in the treatment of hepatitis B infections | HAVCR2, NR1H4, NR1H2 | RBP4 2459/4885ESR2 519/4885ADORA1 552/4885 |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HCCS, SLC10A1, PYGL | RBP4 2939/4885ESR2 1489/4885ADORA1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.